RT Journal Article
SR Electronic
T1 Liver enzyme elevation after <sup>177</sup>Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.120.258533
DO 10.2967/jnumed.120.258533
A1 Hannes Treiber
A1 Alexander Koenig
A1 Albrecht Neesse
A1 Annika Richter
A1 Carsten Oliver Sahlmann
A1 Arne Strauss
YR 2021
UL http://jnm.snmjournals.org/content/early/2021/05/14/jnumed.120.258533.abstract
AB 177Lu-PSMA radioligand therapy (177Lu-PSMA-RLT) is a promising new therapeutic option for patients with metastasized castration-resistant prostate cancer (mCRPC). The spectrum of adverse events with this treatment has to be evaluated. Here, we describe the case of a mCRPC patient with M1c disease (mediastinum, lungs, bones and liver) who presented with elevated liver enzyme levels after 177Lu-PSMA-RLT administration. Pre-treatment 68Ga-PSMA PET/CT showed at least 4 liver lesions with low uptake. Overall, the liver uptake was inhomogeneous. Liver biopsy was performed subsequently.